All stock lists
Disc Medicine, Inc. (IRON)
NASDAQ: IRON · Real-Time Price · USD
Healthcare · Biotechnology
77.30+2.79 (+3.74%)
Insider Score
––Not scored
IRON Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
IRON analyst forecast
IRON analyst consensus
Moderate Buy7 ratings
Buy 7 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
IRON 12-month price target
$136.60+76.9% upsideaverage of 5 firms
$170.00High
$120.00Low
Best analysts covering IRON
- HC Wainwright & Co.75%success rate · 16 calls
- Cantor Fitzgerald67%success rate · 9 calls
- BMO Capital67%success rate · 6 calls
- Stifel57%success rate · 7 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
IRON analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| Jefferies | — | $149.00 | +96.1% | — | 2026-10-21 | |
| Wells Fargo | Overweight | $124.00 | +57.1% | Reiterated | 2026-10-20 | |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-10-20 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-10-20 |
| — | Truist Securities | Buy | — | — | Reiterated | 2026-10-20 |
| Cantor Fitzgerald | Overweight | $170.00 | +115.4% | Reiterated | 2026-10-19 | |
| BMO Capital | Outperform | $120.00 | +56.7% | Reiterated | 2026-10-19 | |
| Wells Fargo | Overweight | $86.00 | +27.8% | Reiterated | 2026-09-16 | |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-09-10 |
| H.C. Wainwright | — | $120.00 | +56.8% | — | 2026-09-10 | |
| Jefferies | — | $128.00 | +67.3% | — | 2026-09-10 | |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-09-02 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-08-06 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-06-16 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-06-10 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-05-14 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-03-02 |
| — | Truist Securities | Buy | — | — | Reiterated | 2026-02-27 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2026-02-17 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-02-17 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-02-17 |
| — | Stifel | Buy | — | — | Reiterated | 2026-02-17 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2026-02-17 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-12-16 |
| — | Truist Securities | Buy | — | — | Reiterated | 2025-11-10 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-10-30 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2025-10-17 |
| — | Wedbush | Outperform | — | — | Reiterated | 2025-10-17 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-10-17 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-08-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-07-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-06-17 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2025-05-12 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-03-18 |
| — | Scotiabank | Sector Outperform | — | — | Reiterated | 2025-03-03 |
| — | Stifel | Buy | — | — | Reiterated | 2025-01-24 |
| — | Scotiabank | Sector Outperform | — | — | Reiterated | 2025-01-22 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-21 |
| — | Stifel | Buy | — | — | Reiterated | 2024-12-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-12-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-13 |
| — | Scotiabank | Sector Outperform | — | — | Reiterated | 2024-11-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-10-28 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-10-15 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-09-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-09-16 |
| — | Wedbush | Outperform | — | — | Reiterated | 2024-08-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-07-10 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2024-06-17 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-06-14 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-05-28 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-05-15 |
| — | Raymond James | Outperform | — | — | Reiterated | 2024-05-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-10 |
| — | Stifel | Buy | — | — | Reiterated | 2024-04-08 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2024-04-02 |
| — | Stifel | Buy | — | — | Reiterated | 2024-04-02 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2024-04-02 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-04-01 |
IRON earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-26 | -1.69 | -1.62 | $150K | $0 |
| 2026-05-05 | -1.55 | -1.65 | $438K | $0 |
| 2026-07-30 | -1.71 | -1.54 | $1.0M | $0 |
| 2026-11-05 | -1.63 | 0.00 | $1.9M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.